{"slug":"pt-141-neuropathy","verification":{"valid":true,"entries":2,"head":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"},"energy":{"passes":2,"tokens_in":30634,"tokens_out":2919,"tokens_total":33553,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"},"provenance":[{"ts":"2026-06-30T01:13:09.236Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: PT 141 for Neuropathy\nSlug: pt-141-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"pt-141\",\"name\":\"PT-141\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"pt-141\",\"name\":\"PT-141\",\"section_title\":\"Why PT-141 might help you\",\"layer\":\"sexual / CNS arousal\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **PT-141** → sexual / CNS arousal\",\"section_headings\":[\"What's breaking down\",\"Why PT-141 might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from pep","response":"{\n  \"slug\": \"pt-141-neuropathy\",\n  \"title\": \"PT-141 for Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive nerve fiber damage and failed repair. Degeneration outpaces regeneration in peripheral nerves or central pathways. Layers include axonal loss, myelin breakdown, reduced blood flow to nerves, inflammation, and disrupted signaling. In diabetic or peripheral cases, this can affect sensation, pain processing, and autonomic functions such as arousal pathways. Mechanical or metabolic stress accelerates breakdown while repair signals remain weak.\\n\\n## Why PT-141 might help you\\n\\nPT-141 acts on melanocortin receptors in the central nervous system to influence arousal circuits.  \\n\\n1. If your neuropathy overlaps with impaired CNS arousal signaling, PT-141 is discussed for its direct action on those brain pathways rather than local tissue repair.  \\n2. If nerve damage has reduced natural arousal responses, the peptide's mechanism targets central initiation of desire and response.  \\n3. Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain. The focus stays on supporting arousal pathways that neuropathy may have disrupted.\\n\\n## How these fit together\\n\\nSingle-compound focus. PT-141 addresses the sexual / CNS arousal layer. No siblings in scope.\\n\\n## What the evidence actually shows\\n\\nNo human trials examine PT-141 for neuropathy itself (preclinical tier only for related compounds; human tier absent here). Studies focus on erectile dysfunction and hypoactive sexual desire disorder. One early crossover study of the related compound MT-II included men with peripheral neuropathic injury among other ED risk factors but measured only erectile response, not neuropathy improvement (mechanistic tier, small n=10). Phase 3 trials of bremelanotide (PT-141) in women with HSDD showed increased desire scores versus placebo but enrolled no n","tokens_in":30634,"tokens_out":2919,"cost":0,"prev":"genesis","hash":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528"},{"ts":"2026-07-17T02:41:08.368Z","model":"owner","action":"voxel_divide","prompt":"","input":"pt-141-neuropathy","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9f7572b6c88115094f42e33f56806e19f07b41b13338368809a8daa3ae848528","hash":"b2e4df7c89ab0cae5472ee618538dd955d0be8970342895a0f37655c36b53228"}]}